PMCB: PharmaCyte Biotech, Inc. Company Value to Net Income

PharmaCyte Biotech Inc. - graphic logo of issuer PMCB

This chart illustrates the price trend for PharmaCyte Biotech (PMCB), which currently carries a PE ratio of -0.20. The company's revenue is driven by the implementation of advanced oncology therapies, including the launch of the Cell-in-a-Box system for treating solid tumors. Financial stability depends on the success of clinical trials and investments, while production capacities are currently being modernized to scale up drug output.

PharmaCyte Biotech Inc. (PMCB) Price to Earnings Ratio: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for PharmaCyte Biotech

- share price and expert price forecast:
Price Performance Chart PharmaCyte|PMCB - Consensus Target
- market capitalization information:
Market Value PharmaCyte Biotech, Inc.|PMCB - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share PharmaCyte Biotech|PMCB - Company Net Assets|Market Cap to Book Value Multiple pharmacyte.com|PMCB - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Capital PharmaCyte Biotech|PMCB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio PharmaCyte|PMCB - Company Aggregate Debts|Debts to Book Capitalization PharmaCyte Biotech, Inc.|PMCB - Company Long-Term Debts|Company Current Liabilities PharmaCyte Biotech|Intermediate Coverage Ratio pharmacyte.com
- earnings and market multiples details:
PMCB - Company Net Income|Forward Earnings PharmaCyte Biotech|PMCB - P/E Multiple|Future Price to Earnings Multiple PharmaCyte|PMCB - PEG Multiple|EV/EBITDA Multiple PharmaCyte Biotech, Inc.|PMCB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year PharmaCyte Biotech|PMCB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pharmacyte.com|PMCB - Earnings growth in current year|Earnings growth forecast for next year PharmaCyte Biotech
Summary company analysis:PMCB, pharmacyte.com
Original product of PharmaCyte Biotech

An investment audit of the issuer requires a thorough analysis of market value relative to earnings. The ratio of market capitalization to net income determines how much an investor is willing to pay for a unit of current earnings. For PharmaCyte Biotech (PMCB), this balance reflects the value of the intellectual capital of the biomedics developing innovative cancer therapies. The trend in the company's estimated P/E reflects the market's confidence in the commercialization of these developments. A prolonged decline in the company's estimated P/E signals a risk of fundamental business devaluation.

Key competitors

TLSI: Company Value to Net Income|Price to Earnings Ratio RNXT (RenovoRx)